S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

NRX Nurexone Biologic Inc

0.59

-0.04 (-6.35%)

Last Updated: 10:34:18

Delayed by 15 minutes

New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries

In January 2023,

To read the full story on AllPennyStocks.com, click here.

Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Nurexone Biologic Charts.

Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Nurexone Biologic Charts.

Nurexone Biologic Inc News

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
Tuesday 21 January 2025 (2 weeks ago) • GlobeNewswire Inc.

NurExone Biologic Secures Master Cell Bank
Wednesday 8 January 2025 (4 weeks ago) • GlobeNewswire Inc.

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
Friday 6 December 2024 (2 months ago) • GlobeNewswire Inc.

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Wednesday 27 November 2024 (2 months ago) • GlobeNewswire Inc.

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
Wednesday 13 November 2024 (3 months ago) • GlobeNewswire Inc.

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
Friday 1 November 2024 (3 months ago) • GlobeNewswire Inc.

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
Wednesday 23 October 2024 (3 months ago) • GlobeNewswire Inc.

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
Thursday 26 September 2024 (4 months ago) • GlobeNewswire Inc.

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
Thursday 12 September 2024 (5 months ago) • GlobeNewswire Inc.

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
Friday 6 September 2024 (5 months ago) • GlobeNewswire Inc.

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Wednesday 28 August 2024 (5 months ago) • GlobeNewswire Inc.

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
Friday 23 August 2024 (5 months ago) • GlobeNewswire Inc.

More Nurexone Biologic Inc News Articles

Sicav Total Return Flexi...

WisdomTree Silver

BNP Paribas Issuance

Sg Etn World Hydrogen

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions